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Abstract
Background: Elevated plasma total homocysteine is an independent risk factor for cardiovascular disease and a
sensitive marker of the inadequate vitamin B12 and folate insufficiency. Folate and vitamin B12 have a protective
effect on cardiovascular disease. This population based study was conducted to evaluate the plasma total
homocysteine, folate, and vitamin B12 in healthy Iranian individuals.
Methods: This study was a part of the Cardiovascular Risk Factors Survey in the Population Lab Region of Tehran
University has been designed and conducted based on the methodology of MONICA/WHO Project. A total of
1214 people aged 25–64 years, were recruited and assessed regarding demographic characteristics,
homocysteine, folate, and vitamin B12 levels with interview, questionnaires, examination and blood sampling.
Blood samples were gathered and analyzed according to standard methods.
Results: The variables were assessed in 1214 participants including 428 men (35.3%) and 786 women (64.7%).
Age-adjusted prevalence of hyperhomocysteinemia (Hcy≥15 µmol/L) was 73.1% in men and 41.07% in women (P
< 0.0001). Geometric mean of plasma homocysteine was 19.02 ± 1.46 µmol/l in men and 14.05 ± 1.45 µmol/l in
women (P < 0.004) which increased by ageing. Age-adjusted prevalence of low serum folate level was 98.67% in
men and 97.92% in women.  Age-adjusted prevalence  of  low  serum  vitamin  B12  level  was  26.32%  in men
and 27.2% in women. Correlation coefficients (Pearson's r) between log tHcy and serum folate, and vitamin B12
indicated an inverse correlation (r = -0.27, r = -0.19, P < 0.0001, respectively).
Conclusion: These results revealed that the prevalence of hyperhomocysteinemia, low folate and vitamin B12
levels are considerably higher than other communities. Implementation of preventive interventions such as food
fortification with folic acid is necessary.
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Background
Homocysteine (Hcy) is a nonessential sulfur-containing
amino acid formed from the demethylation of an essen-
tial amino acid, methionine [1]. Plasma folate and vita-
min B12 influence homocysteine metabolism as
cosubstrate and cofactor, respectively [2]. Elevated plasma
total homocysteine (tHcy) has been linked both to the
inadequate status of vitamin cofactors (i.e. folate, vitamin
B12 and B6) and to genetic defects in enzymes involved in
homocysteine metabolism [3]. Genetic causes are mostly
defects in the enzymes that control homocysteine metab-
olism. It is now believed that metabolism of homo-
cysteine may be race and ethnic dependent [4].
Elevated plasma levels of homocysteine increase the risk
for atherosclerosis, stroke, myocardial infarction, possibly
Alzheimer's disease, cognitive impairment in the elderly,
birth defects in pregnant women, and all-cause mortality
[5]. Besides, hyperhomocysteinemia (HHcy) may induce
changes in DNA that may result in procarcinogenic effects
[6]. On one hand, plasma homocysteine is a very sensitive
marker of folate and vitamin B12 status; plasma homo-
cysteine levels are inversely related to plasma levels of
these substances. The increase in homocysteine level
occurs long before classic deficiency of folate and vitamin
B12 become evident [7]. Inadequate levels of these vita-
mins have important health consequences that may be
independent of their role in homocysteine metabolism
[8]. Folate and vitamin B12 status has been related to the
occurrence of neural tube defects. Other potential mani-
festations of folate deficiency include neurological and
neuropsychiatric disorders, and preneoplastic conditions.
Furthermore, folate deficiency has been associated with a
predisposition to atherosclerotic cardiovascular disease
[9,10]. Folate status may be negatively influenced by inad-
equate intake, genetic polymorphisms and interactions
with various drugs [6]. Folate and vitamin B12 have a pro-
tective association with cardiovascular disease that can be
partly explained by mechanisms independent of homo-
cysteine, as suggested by several recent studies [11,12]. On
the other hand, folate and cobalamin status are important
modifiable determinants of plasma total homosysteine in
the general population, and negative relations between
plasma total homocysteine concentrations and these vita-
mins are observed even within their established normal
and subnormal concentration ranges [13]. Testing for
hyperhomocysteinemia may therefore be useful to assess
the nutritional status in humans. Estimation of the pro-
portion of cases with high homocysteine concentrations
that can be attributed to inadequate vitamin status is com-
plicated by the lack of a standard definition of a high total
homocysteine concentration. In the absence of a defini-
tion based on increased risk for an adverse health out-
come, such as vascular disease, upper reference limits
from samples of healthy persons without established risk
factors for high homocysteine concentrations have been
used to define a high total homocysteine concentration
[13-16].
Although the distribution of plasma concentrations of
homocysteine has been reported in some populations,
there is little available information describing homo-
cysteine concentrations in the healthy Iranians [17]. In the
present study, total homocysteine, folate, and vitamin
B12 concentrations were measured in 1214 healthy Irani-
ans as part of "Tehran Homocysteine Survey". This study
describes the distributions of total homocysteine, folate,
and vitamin B12 concentrations altogether in a sample of
healthy Iranians.
Methods
Study design
The present data are part of a cross – sectional study
(designed as Cardiovascular Risk Factor Survey in the Pop-
ulation Lab Region of Tehran University) arranged and
conducted based on methodology of MONICA (Multina-
tional Monitoring of Trends and Determinants in Cardio-
vascular Diseases)/WHO (World Health Organization)
project [1,19] by EMRC (Endocrinology and Metabolism
Research Center) affiliated with Tehran University of
Medical Sciences (TUMS). We recruited 1573 apparently
healthy residents of 17th district of Tehran – capital city of
Iran – randomly chosen by one stage cluster random sam-
pling from a group of 255337 people. This south western
district of Tehran is the most crowded one, with low
income inhabitants. Because of its unique characteristics,
there has been selected as Tehran University Population
Lab Region.
Subjects and study criteria
Totally, 1573 healthy (without any history of severe renal,
liver and cardiac dysfunction) participants (615 men and
958 women) aged 25–64 years were recruited: 140 were
not interested to take part in this part of study, 152 did not
meet the inclusion criteria (being healthy and 25–64 years
old), and 67 had incomplete laboratory data.
Therefore, our analyses are based on 1214 participants
(428 men and 786 women) with complete data on
plasma total homocysteine, folate, and vitamin B12 con-
centrations. Exclusion criteria included known coronary
heart disease (CHD), systemic illness, serious organ dis-
ease, proliferative and endocrine diseases, alcoholism,
Table 1: Based Homocysteine Ranges in Our Study [23]
Normal tHcy < 15 µmol/L
Mild HHcy tHcy  15 – 30 µmol/L
Moderate HHcy tHcy  30 – 100 µmol/L
Severe HHcy tHcy > 100 µmol/LBMC Public Health 2006, 6:29 http://www.biomedcentral.com/1471-2458/6/29
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current pregnancy, current use of vitamins or other sup-
plements, anticonvulsant and anticancer therapy. Partici-
pants underwent a standardized medical history, physical
examination, anthropometric measurements and labora-
tory tests. Personal and lifestyle information were
obtained by using modified MONICA questionnaires
[18]. All respondents gave their written informed consent.
Our research protocol was approved by the EMRC ethics
committee and was conformed to the principles embod-
ied in the declaration of Helsinki.
Laboratory analyses
Fasting blood samples were obtained in the early morning
hours after 12 hours fast. The plasma samples were put in
a cooled container and immediately carried to the EMRC
laboratory, where the plasma was separated within 2
hours of sampling by centrifugation (20 min, RT, at 2000
RPM) and aliquots were stored at -70°c until determina-
tions. In this part of the study, the following parameters
were analyzed: total plasma homocysteine, serum vitamin
B12 and serum folate. Plasma total homocysteine concen-
trations (the sum of homocysteine and homocysteine-
cysteine mixed disulfides, free and protein-bound) were
determined on frozen samples by HPLC (High-perform-
ance Liquid Chromatography) method (KNAUER, Ger-
many), coupled with fluorescence detector. The method
has been validated over a linearity range of 1–100 µmol/
L from plasma. The intra-assay and inter-assay coefficient
of variation for homocysteine samples were 3.9% and
5.8% respectively. Folate and vitamin B12 were measured
simultaneously in the frozen serum aliquot by a double
labeled radioassay kit (ICN Pharmaceuticals, New York).
The intra-assay coefficient of variation for folate and vita-
min B12 were 6.9% and 6.1%, respectively. The inter-
assay coefficient of variation for folate and vitamin B12
were 7.5% and 6.8%, respectively.
Statistical analyses
The distributions of total homocysteine, folate and vita-
min B12 concentrations were skewed to the right. There-
fore values were logarithmically natural transformed (Ln)
to promote normality and presented as geometric mean
and 95% confidence intervals. Various quartiles of homo-
cysteine were estimated in analyses stratified according to
the strongest predictors of mean total homocysteine con-
centrations in multivariate analysis: sex, age, folate score
and vitamin B12 score. All values were calculated as mean
± SD (standard deviation) for the total group and sepa-
rately by sex and age. Associations between categorical
variables were reported by Chi-square test. Continuous
variables were compared by Student's t test. A P value <
Table 3: Proportion of individual in each homocysteine classes according sex and age groups
Age range <10 10–15 15–30 30–100 >100
Male 25–34 5.5% 28.5% 55.2% 10.9% 0
35–44 5% 27.7% 60.4% 6.9% 0
45–54 0% 20.9% 67.2% 11.9% 0
55–64 1.1% 11.6% 73.7% 13.7% 0
Female 25–34 21.5% 45% 31.1% 2.3% 0
35–44 15.7% 41.65 40.5% 2.2% 0
45–54 17.5% 38% 41.6% 3% 0
55–64 10.5% 32.3% 54.9% 2.3% 0
Table 2: Clinical characteristics, risk factors and nutritional state of the study population
Characteristic Male Female P-value
Age 41.9 ± 12.6 40.8 ± 11.7 0.15
BMI (kg/m2) 26.5 ± 7.3 29.2 ± 9.2 0.0001
Cigarette Smoking 31.7% 5.7% 0.0001
Diabetes 9.7% 11.8% 0.23
Total cholesterol (mg/dl) 187 ± 39.5 198 ± 46.1 0.0001
LDL(mg/dl) 96.5 ± 26.2 102.4 ± 30 0.004
HDL(mg/dl) 54.2 ± 16.3 61.1 ± 18 0.0001
Triglyceride(mg/dl) 196.8 ± 174.4 184.3 ± 141.4 0.1
HTN 46.4% 39.2% 0.01
Vitamin B12 intake (µgr/day) 2.9 ± 2.6 2.2 ± 2.07 0.01
Folic acid intake (µgr/day) 294 ± 73.7 270 ± 60.7 0.05BMC Public Health 2006, 6:29 http://www.biomedcentral.com/1471-2458/6/29
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0.05 was considered significant. Data were analyzed by
using Statistical Package for Social Sciences (SPSS) version
11.5 software.
A folate concentration less than 11 nmol/L [8,20,21] and
a vitamin B12 concentration less than 185 pmol/L[8,22]
served as the criterion for defining low vitamin levels. We
also defined hyperhomocysteinemia (HHcy) as Table 1
demonstrates.
Results
The group studied contained 428 (35.3%) male and 786
(64.7%) female 25–64-y-old individuals. Table 2 shows
the clinical characteristics, nutritional state and other risk
factors in the study participants.
Proportion of individual in each homocysteine classes has
been shown in table 3. Hyperhomocysteinemia (tHcy≥ 15
µmol/L) was detected in 313 (crude prevalence: 73.1%,
age-adjusted: 73.1%) males and 330 (crude prevalence:
42%, age-adjusted: 41.07%) females which was signifi-
cantly higher in men than women (P < 0.0001). Although
crude and age-adjusted prevalence of low folote levels
(<11 nmol/L) were observed respectively in 98.8% and
98.67% of males and 97.9% and 97.92% of females, the
difference between sexes was not statistically significant (P
= 0.281). Crude and age-adjusted prevalence of low vita-
min B12 levels (<185 pmol/L) were determined respec-
tively in 26.8% and 26.32% of male and 27.3% and
27.2% of female individuals but the difference was not
statistically significant either (P = 0.846).
Crude prevalence of Hyperhomocysteinemia for 45–54-
year and 55–64-year-old age groups among both males
and females were 79.1%, 87.4% and 44.6%, 57.1%,
respectively (Table 4).
Notably, 12% (n = 146) of participants had normal total
homocysteine concentrations, but mild and moderate
hyperhomocysteinemia were detected in 47.6% (n = 578)
and 5.4% (n = 65) of individuals, respectively. Crude, age
and sex-adjusted prevalence of hyperhomocysteinemia in
total participants were 53% and 56.2%, respectively.
Crude prevalence of low folate, and vitamin B12 levels
were detected in 98.2% (age and sex adjusted: 98.3%) and
27.1% (age and sex-adjusted: 26.77%) of total subjects
respectively.
Correlation coefficients (Pearson's r) between log tHcy
and serum folate, and vitamin B12 indicated an inverse
correlation (r = -0.27, r = -0.19, P < 0.0001, respectively).
The geometric mean of total homocysteine level is the
highest in 55–64-year-old age group as Table 5 presents.
But in this age group, men had higher homocysteine con-
centrations than women.
The lowest level of serum folate was considered in both
male and female 45–54-year age groups. The lowest level
of vitamin B12 was determined in male 45–54-year-old
and female 35–44-year-old age groups. In general, geo-
metric mean of homocysteine was higher in men than
women, and increased by age, but geometric mean of
serum folate in all age groups were higher in men than
women. Geometric mean of serum vitamin B12 was
higher in all female age groups (except 35–44-year-old)
than similar male age groups. Overall geometric mean of
total homocysteine, folate, and vitamin B12 levels were
15.64 ± 1.50 µmol/L, 3.94 ± 1.67 nmol/L, 262.88 ± 1.82
pmol/L, respectively.
Men had significantly higher mean plasma homocysteine
concentration than women (geometric mean = 19.02 ±
1.46 µmol/L, compared with 14.05 ± 1.45 µmol/L, P =
0.004) and lower mean serum folate levels than women
(geometric mean = 3.66 ± 1.65 nmol/L compared with 4.1
± 1.67 nmol/L, P < 0.0001). Mean serum vitamin B12 was
not significantly higher in women (geometric mean =
269.27 ± 1.75 pmol/L) than in men (geometric mean =
251.39 ± 1.94 pmol/L, P = 0.063).
Distribution of participants according to their total homo-
cysteine, folate, and vitamin B12 level quartiles (Q1–Q4)
are displayed in Table 6.
Table 4: Prevalence of Hyperhomocysteinemia and Low Vitamin Concentrations According to Sex and Age Group
sex Age-Group(Y) N HHcy (%) Low Folate (%) Low Vitamin B12 
(%)
Male 25–34 165 66.1% (109) 98.7 24.5
35–44 101 67.3% (68) 97.8 26.1
45–54 67 79.1% (53) 100.0 27.4
55–64 95 87.4%(83) 98.9 31.1
Female 25–34 302 33.4% (101) 97.9 24.7
35–44 185 42.7% (79) 98.3 28.7
45–54 166 44.6% (74) 98.1 31.2
55–64 133 57.1% (76) 96.9 26.6BMC Public Health 2006, 6:29 http://www.biomedcentral.com/1471-2458/6/29
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By increasing age, there was a decreasing frequency in first
quartile of homocysteine, while in fourth of homo-
cysteine quartile in both sexes, an increasing frequency
was considered by aging.
Regarding homocysteine quartiles, the highest distribu-
tion was found in male 55–65-year-old and female 25–
34-year-old age groups. According to folate quartiles, the
highest distribution was seen in male 45–54-year-old and
female 55–64-year-old age groups.
Thresholds of each tHcy, folate and vitamin B12 quartiles
were: 12.20, 2.80 and 174.00 µmol/L; 15.00, 4.00 and
285.00 µmol/L; 20.20, 5.40 and 378.00 µmol/L, respec-
tively.
Discussion
Many studies have shown that elevated total homo-
cysteine concentration is an independent risk factor for
cardiovascular diseases [24-27]. Total plasma homo-
cysteine levels are higher in men than in women and at
older ages [25,23]. Folate and vitamin B12 are the major
nutritional determinants of homocysteine levels [28]. Per-
sons with low circulating folate or vitamin B12 concentra-
tions have higher fasting total homocysteine
concentrations [13,23]. Elevated fasting homocysteine
concentrations in turn, are usually normalized by treat-
ment with folic acid and vitamin B12 [29,30]. Although
epidemiologic surveys have determined total homo-
cysteine concentrations in order to identify the prevalence
of hyperhomocysteinemia, estimation of these cases is
complicated by the lack of a standard definition of a high
total homocysteine concentration [8,15,16,30].
In our study, the prevalence of hyperhomocysteinemia
and low folate and vitamin B12 levels were higher than
other populations [2,8,16,17,31]. Prevalence of hyperho-
mocysteinemia and the mean homocysteine concentra-
tions were higher in men than in women and at older
ages. The age and sex differences in total plasma homo-
cysteine levels observed in this study are consistent with
observations from published studies in large and small
sample size of adult men and women in some reported
populations [32,33]. Plasma homocysteine concentra-
tions are increased with age and higher in men than in
women [25,31,34,35].
For every 20 years of age, Hcy increases on average by 1.3
µmol/L [36]. The reasons for higher homocysteine con-
centrations at older ages are not well understood,
although changes in renal function and impaired renal
metabolism of homocysteine may be involved [37,38].
Furthermore, elevated plasma homocysteine concentra-
tions in older populations can also be attributed to low
blood folate concentrations [39] and an increased inci-
dence of vitamin B12 deficiency resulting from malab-
sorption of vitamin B12 by the aging gut [40]. Men have
average 1 µmol/L higher Hcy values than women [34,36].
Higher homocysteine concentrations in males than in
females could be due to larger muscle mass and greater
creatine phosphate synthesis in men, [1] lowering effect of
estrogens in women [41] and differences in vitamin status
[25] and homocysteine formation between sexes [1]. Part
of the relationship with age in women might be explained
by menopause, since the homocysteine concentration was
found to be higher in post-menopausal women compared
with premenopausal women [34].
In present study, mean total homocysteine concentration
is notably higher than what other surveys have reported
[2,8,16,17,31]. In addition, we observed that the preva-
lence of mild hyperhomocysteinemia (15< Hcy <30
µmol/L) was 47.6%. Probably, the condition of homo-
cysteine distribution and concentration of values around
ranges 10–30 µmol/L and low prevalence of normal total
homocysteine concentrations in this sample, caused
Table 5: Mean Total Homocysteine, Folate and Vitamin B12 According to Sex and Age Group
Characteristics Male Age Group (Y) Female Age Group (Y)
25–34 35–44 45–54 55–64 25–34 35–44 45–54 55–64
Participants (N) 165 101 67 95 302 185 166 133
Geometric mean
Hcy µmol/L
CI 95%
18.0
16.9–19.1
18.5 
17.2–19.9
19.5
17.9–21.1
21.3
19.9–22.8
13.3
12.8–13.9
14.1
13.3–14.9
14.2
13.4–15
15.6
14.7–16.7
Geometric mean
Folate nmol/L
CI 95%
3.6 
3.4–3.9
3.7 
3.3–4.2
3.3 
2.9–3.7
3.9 
3.6–4.3
4.0 
3.8–4.3
4.1 
3.8–4.5
4.0 
3.7–4.3
4.3
4.0–4.7
Geometric mean
Vit B12 nmol/L
CI 95%
255.8 
232–281
262.6
224–308
235.1
194–284
244.1
216–276
256.1
259–294
276.5
236–278
264.8
241–290
278.0
251–307BMC Public Health 2006, 6:29 http://www.biomedcentral.com/1471-2458/6/29
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increase in the mean homocysteine level. In other words,
although the mean homocysteine level is high, the sever-
ity of hyperhomocysteinemia is not that much. Further-
more, serum folates, and vitamin B12 levels compared to
values from various countries, indicate that prevalence of
low levels of folate, and vitamin B12 is higher in our sam-
ple [2,8,16,17,31]. It could be due to geographical varia-
tions, racial and ethnic differences [17], genetic causes,
different lifestyle, and inadequate intake of B vitamins
and folate, inaccurate cooking of vegetables and not
implementing fortification of grain products with folic
acid in our country. As it has been shown in table 1 it
seems that low daily intake of vitamin B12 and folic acid
is the eventual cause of low folate levels in our study pop-
ulation. Prolonged cooking of vegetables may destroy up
to 90% of folate content [42]. Candidate genes can regu-
late plasma homocysteine concentrations, especially
methylene tetrahydrofolate reductase (MTHFR) and cys-
tathionine-β-synthase (CBS) genes. Recent studies have
shown the importance of DNA polymorphisms in the
genes for enzymes involved in homocysteine metabolism
[31]. Moreover, it has been reported that rural-to-urban
migrant population living in urban slums undergoing
stressful socio-economic transition are likely to have low
intakes of folate, and vitamin B12, which may have an
adverse impact on plasma levels of homocysteine [43].
Limitations of the present investigation include not
assessed several factors that might be associated to ele-
vated tHcy, such as creatinine and vitamin B6 concentra-
tions.
Our results confirm the findings of other observations
that elevated total homocysteine concentrations are
potentially attributable to low vitamin levels. Because
folate is an established predictor of homocysteine concen-
tration, it would be useful to investigate the effect of folate
enrichment of foods on homocysteine concentration in
the current Iranian population. Although firm therapeutic
guidelines are lacking, consideration should be given to
treatment as a primary prevention measure for patients
whose baseline homocysteine level exceeds 15 µmol/L.
Folic acid supplementation in a dose of 400–800 mg/day
effectively lowers plasma homocysteine levels in a signifi-
cant percentage of individuals, with the higher dose being
needed by many to achieve a meaningful reduction in
plasma homocysteine. However some patients will not
respond to this dose of folate. This makes close follow-up
and periodic monitoring of homocysteine levels essential.
The only way to truly know if folate treatment is being
effective is to recheck the homocysteine level [44]. This
guideline could be followed by family physicians.
Another essential prevention guideline is planning for for-
tification of enriched grain products with folic acid in Iran
like many other countries [45]. The main motivation
behind fortification is to abate the occurrence of neural
tube defects (NTDs), a birth defect shown to be responsive
to folic acid administration [46]. A secondary benefit of
fortification might be a reduction in the incidence of car-
diovascular disease [47] and probably certain cancers,
[48] the occurrence of which are associated with low
folate status. The success of fortification was quickly seen
[45] with the declining incidence of folate deficiency and
a concurrent decrease in the incidence of elevated plasma
total homocysteine [49].
Although the distribution of plasma concentrations of
homocysteine, folate, and vitamin B12 has been reported
in some populations of other countries, there is little or
no available information describing these parameters in
healthy Iranians and their relations to gender and age.
There is only one study that has reported homocysteine
levels in Iranians. In this study, 402 participants 15 years
of age or older of southwest of Iran were monitored and
the mean plasma homocysteine level was reported signif-
icantly higher in men than women [17].
Table 6: Distribution of Participants in Each Sex and Age Group Based on Their tHcy, Folate and Vitamin B12 Quartiles
tHcy Quartiles(%) Folate Quartiles (%) Vitamin B12 Quartiles (%)
Sex Age 
Group 
(y)
123412341234
Male 25–34 17.7 19.5 25.6 37.2 29.0 27.1 25.2 18.7 23.3 23.3 32.1 21.4
35–44 11.9 20.8 23.8 43.6 27.8 23.3 24.4 24.4 25.3 17.6 33.0 24.2
45–54 1.5 26.9 32.8 38.8 40.0 25.0 23.3 11.7 25.8 27.4 25.8 21.0
55–64 3.2 11.6 28.4 56.8 28.1 20.2 24.7 27.0 30.3 29.2 18.0 22.5
Female 25–34 36.9 32.9 18.3 12.0 22.3 26.6 23.8 27.3 22.6 21.6 28.9 26.8
35–44 33.0 26.5 25.9 14.6 20.5 27.5 21.6 30.4 24.9 33.3 15.8 26.0
45–54 32.9 26.1 24.8 16.1 23.2 22.6 23.9 30.3 28.4 20.6 25.2 25.8
55–64 19.5 26.3 31.6 22.6 18.2 21.5 26.4 33.9 23.0 23.0 25.4 28.6BMC Public Health 2006, 6:29 http://www.biomedcentral.com/1471-2458/6/29
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The cost effectiveness of assessment of homocysteine as a
cardiovascular risk factor is important. The cost for homo-
cysteine measurement is higher than other risk factors at
individual level. However, since it has been reported as a
highly potential risk factor of CHD [1,4,11] which can be
modified easily by food supplementation with folate and
vitamin B12, its assessment is valuable and has cost bene-
fit at the public health level.
In conclusion, we found the association between plasma
homocysteine concentration and age and sex, and blood
levels of vitamins by using data from a cross-sectional
study based on MONICA/WHO similar to other studies
worldwide. Also, we reported that plasma homocysteine
concentration was inversely associated with folate and
vitamin B12 levels. The variables sex and age were not
independently associated with homocysteine levels when
other variables were considered. Because this study used
cross-sectional data, it was not possible to evaluate the
data in terms of cause-and-effect relations.
Conclusion
So far, little has been published on distribution of total
homocysteine concentrations in healthy Iranians. This
study describes the distributions of total homocysteine,
folate, and vitamin B12 concentrations altogether in a
sample of healthy Iranians. According to significance of
genetic and ethnic factors on total homocysteine level, we
are conducting a study to observe Iranians' MTHFR
(methylene tetrahydrofolate reductase) and CBS (cystath-
ionine-β-synthase) polymorphisms. In addition, our clin-
ical trials are underway to investigate the impact of folic
acid supplements on plasma homocysteine concentra-
tions and hypertension in Iranian population. Since there
are little or no available information in our country, it is
possible that future studies could reveal excess determi-
nants of hyperhomocysteinemia.
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